immatics is developing cancer drugs that help to activate the self defense mechanisms of the human body.
Our goal is to support patients and physicians with new options in the fight against various cancers.
Our means are synthetic peptides that specifically activate specialized white blood cells of the patient’s immune system against cancer cells.
Our first product for the treatment of kidney cancer, IMA901, has entered a Europe-wide multi-center Phase II clinical trial in 2007. Our second product for the treatment of colorectal cancer, IMA910, has recently entered another large Phase I/II clinical trial and is now open for patient recruitment.
- -- 17 June 2009
immatics biotechnologies significantly improves XPRESIDENT™ technology platform - Tuebingen, June 17, 2009 – immatics biotechnologies today announced the ... read more
- -- 02 March 2009
immatics completes patient recruitment in phase II study with cancer vaccine IMA901 for renal cell cancer - Tuebingen, March 2, 2009 – immatics biotechnologies GmbH today announced having completed patient ... read more
- -- 26 January 2009
immatics wins 29th German Industry's Innovation Award (Innovationspreis der deutschen Wirtschaft) - Tuebingen, January 26, 2009 – immatics biotechnologies GmbH today announced that it has been awarded the 29th ... read more
Renal cell cancer phase II clinical trial
Drug: Peptide-based renal cell cancer vaccine IMA901...read more
Participating countries: Germany, Austria, Switzerland, U.K., Spain, Bulgaria, Hungary, Poland, Romania, Slovakia
Colorectal cancer phase I/II clinical trial
Drug: Peptide-based colorectal cancer vaccine IMA910...read more
Participating countries: Germany, Belgium, U.K., Hungary, Serbia, Latvia, Poland, Romania